Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Appointed director
|
InspireMD, Inc. (NSPR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/12/2023 |
8-K
| Quarterly results |
10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/08/2023 |
8-K
| Quarterly results |
07/21/2023 |
8-K
| Quarterly results |
05/23/2023 |
8-K
| Investor presentation |
05/16/2023 |
8-K
| Quarterly results |
03/30/2023 |
8-K
| Quarterly results |
03/20/2023 |
8-K
| Quarterly results |
11/08/2022 |
8-K
| Quarterly results |
09/01/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
08/11/2022 |
8-K
| Quarterly results |
06/03/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
05/20/2022 |
8-K
| Quarterly results |
05/10/2022 |
8-K
| Quarterly results |
03/08/2022 |
8-K
| Quarterly results |
02/28/2022 |
8-K
| Quarterly results |
01/10/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
12/07/2021 |
8-K
| Quarterly results |
11/04/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
10/13/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/30/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/10/2021 |
8-K
| Quarterly results |
07/26/2021 |
8-K
| Other Events, Financial Statements and Exhibits
Docs:
|
"InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS Tel Aviv, Israel— July 23, 2021 - InspireMD, Inc. , developer of the CGuard™ Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company’ s U.S. registration C-Guardian trial of CGuard EPS. The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device . These are the first of 315 patients who are expected to be enrolled in the trial and trea..." |
|
06/29/2021 |
8-K
| Quarterly results |
06/08/2021 |
8-K
| Quarterly results |
05/27/2021 |
8-K
| Quarterly results |
05/20/2021 |
8-K
| Quarterly results |
05/12/2021 |
8-K
| Quarterly results |
05/11/2021 |
8-K
| Quarterly results |
05/10/2021 |
8-K
| Quarterly results |
04/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits
Docs:
|
"InspireMD Provides Corporate Update for Shareholders Tel Aviv, Israel— April 19, 2021 - InspireMD, Inc. , developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease , today provided an update of recent corporate developments. ● Shareholders approved a 1:15 reverse stock split, reducing the number of outstanding shares from 118 million to 7.9 million shares, which will take effect following the close of trading on April 26, 2021 ● Today, the Company submitted its application to join the Nasdaq Capital Market, which the Company views as more attractive to a broader range of investors than its current listing InspireMD CEO Marvin Slosman commented, “The fundamentals of our business remain sound and consis..." |
|
04/14/2021 |
8-K
| Quarterly results |
03/17/2021 |
8-K
| Quarterly results |
03/10/2021 |
8-K
| Quarterly results |
|
|
|